Background: We hypothesized that survival varied significantly between retroperitoneal soft tissue sarcoma (STS) and extremity/trunk STS. This study explored the reasons for the different outcomes and identified patient characteristics for survival. Methods: This retrospective study identified 213 consecutive patients with localized primary STS from January 2002 to July 2013, including 47 retroperitoneal STS (22.1%) and 166 extremity/trunk STS (77.9%). Local failure-free survival (LFFS), distant metastasis-free survival (DMFS) and overall survival (OS) were constructed by the Kaplan-Meier method. Univariate Cox proportional hazards regression models were fit to assess the ability of patient characteristics to predict survival. Results: At presentation, patients with retroperitoneal STS had larger tumor size (median size 18 cm vs. 6 cm; P < 0.001) and positive margin (21.3% vs. 8.4%; P = 0.014), and less often received radiotherapy (2.1% vs. 45.8%; P < 0.001). The median follow-up time for the entire population was 68 months (range, 5-127 months). Local recurrence was more frequent in patients with retroperitoneal STS compared with patients with extremity/trunk STS (53.2% vs. 28.3%; P = 0.001). LFFS and OS were lower in patients with retroperitoneal STS than extremity/trunk STS, with 5-year LFFS (50% vs. 74.3%; P < 0.001) and 5-year OS (65.4% vs. 77.5%; P = 0.017), respectively. Conclusion: Retroperitoneal STS was associated with significantly worse survival compared with extremity/trunk STS. Larger tumor size, more patients with positive margin and fewer patients received radiotherapy in retroperitoneal group may result in worse survival compared with extremity/trunk disease.
Introduction
Soft tissue sarcomas (STS) are a group of very heterogeneous tumors accounting for less than 1% of all malignancies. Of all STS, about 15% occur in the retroperitoneum (1) . Although the natural behavior and outcomes of STS are dependent of the age of the patient, location, depth, size and resectability of the tumor, as well as of histology, grade, local recurrence and distant metastasis (2, 3) . The NCCN guideline of STS classifies this disease into retroperitoneal and extremity/trunk according to tumor location, not by other factors.
The conservative surgery is the most important primary treatment for patients with extremity/trunk STS. Randomized trials demonstrated that the combination of radiotherapy (RT) with conservative surgery reduced local recurrence from 30% to 10-15% (4) (5) (6) (7) . Based on these studies, conservative surgery plus RT become the mainstay treatment modality in patients with extremity/trunk STS. To date, surgical resection with negative margin is the only standard treatment for retroperitoneal STS. However, the outcomes of surgery alone are not satisfying; with 5-year local recurrence ranging from 22% to 62% and up to 75% deaths resulted from uncontrolled local diseases (8) (9) (10) (11) . In comparison with extremity/trunk STS, the prognosis of retroperitoneal STS is significantly worse. However, few studies compare the outcomes of the two locations directly.
The aim of this study was to assess the effect of tumor location on the survival in patients with STS and explore the reasons for the different outcomes. This study also identified patient, tumor and treatment characteristics that may predict subsequent local recurrence and survival in two locations.
Materials and methods

Patients
We retrospectively reviewed adult patients with localized primary STS who presented from Cancer Hospital of Fudan University and Hangzhou First people hospital between January 2002 and July 2013. We excluded patients diagnosed with rhabdomyosarcoma because it was dissimilar in their characteristics, management and prognosis. Histological diagnosis was confirmed in each case through review of the slides by a pathologist. Patients were divided into two groups: the first was comprised of patients with STS located in extremity and trunk wall, the second group included patients with retroperitoneal STS. This study was approved by review board of Cancer Hospital of Fudan University and Hangzhou First people hospital.
The tumor classified histological into low-(Grade I) and or highgrade (Grade II-III) using the French Federation of Cancer Centers grading system (12) . Tumor size was divided into small (≤5 cm) or large (>5 cm) group by the greatest diameter. Patient age was categorized for analysis as ≤50 years or >50 years. We reviewed the medical records and recorded the following information: age, gender, histopathological subtype, size, grade, surgical margins status, lymph node status, treatment modality and toxicities.
Treatment
The patients with tumor located extremity and trunk underwent structure-and function-preserving surgical resections. Gross total resection was performed in patients with retroperitoneal. Some patients received postoperative RT and/or chemotherapy (generally doxorubicin and ifosfamide) based on prognostic factors predicting higher risk of local recurrence and distant metastasis. Conventional RT was delivered using 8 MV linear accelerator photon in 2 Gy/ fraction. Field borders were either the whole compartment, or proximal and distal margins of 5 cm in non-compartmental lesions. An initial dose of 50 Gy was delivered at first. Afterward, an additional of 10-20 Gy boost was given to tumor bed plus 3 cm margins. Threedimensional conformal radiotherapy (3D-CRT) and intensity modulation radiated therapy (IMRT) were adopted since 2007. The radiation dose and definition of target volume in 3D-CRT or IMRT was same with conventional RT. Few patients did not receive full dose RT for protecting organs at risk adjacent radiation field.
Follow-up
The items of follow-up included physical examination, chest CT and ultrasonography of the primary site, with additional MRI when local recurrence was suspected. The patients were followed at 3-month interval in the first 2 years, 6-month interval in the following 3 years and yearly thereafter. The major endpoint of this study was local recurrence, which was defined as the first pathological verified tumor of the same histological type, within or contiguous to the previously treated tumor bed at least 3 months after treatment. Distant metastasis was defined by clinical, pathological or radiologic evidence of systemic disease spread outside the primary tumor site.
Statistical analysis
Descriptive data was compared using Pearson Chi-square test or Fisher's exact test, where appropriate. For survival analysis, survival curves were constructed using the Kaplan-Meier method and logrank test assessed statistical difference. Univariate Cox proportional hazards regression models were fit to assess the ability of patient characteristics to predict LFFS, DMFS and OS. A two-sided P value of <0.05 determined statistical significance. All statistical analyses were performed using SPSS 17.0 software package (Chicago, IL, USA).
Results
Patient demographics and clinicopathological characteristics
We retrospectively reviewed 276 consecutive adult patients with localized primary STS during the period of January 2002 to July 2013. We excluded those patients with secondary sarcoma (n = 6), who received amputation or the treatment for palliative purpose (n = 9), surgically unresectable disease at presentation (n = 7), rhabdomyosarcoma (n = 30) and those without follow-up data (n = 11). The remaining 213 patients were included in this study; 47 of whom were retroperitoneal STS and 166 were extremity/trunk STS. Table 1 presents the patient demographics and clinicopathological characteristics of this study population.
Retroperitoneal STS patients
The median age of patients was 53 years (range, 30-86 years). Nearly half patients were >50 years old (53.2%) and men (51.1%). Liposarcoma (57.4%) was the most commonly diagnosed histology subtype, including 25.5% myxiod liposarcoma (n = 12), 14.9% well-differentiated liposarcoma (n = 12), 19.1% dedifferentiated liposarcoma and 19.1% other subtype liposarcoma (n = 7). Tumor size ranged from 3 to 42 cm, with a median size of 18 cm and most patients (87.2%) were larger than 5 cm. Ten patients (21.3%) were low grade, whereas 41 (87.2%) presented as high grade tumors. Positive margin were found in 10 patients (21.3%). Few patients received chemotherapy (n = 3, 6.4%) and radiotherapy (n = 1, 2.1%). No patient developed lymph node metastasis.
Extremity/trunk STS patients
A total of 166 patients were located in extremity and trunk wall. Ages ranged from 16 to 86 years with a median age of 52 years. There were also nearly half patients (54.8%) were > 50 years old and male (57.8%). Undifferentiated high-grade pleomorphic sarcoma (UPS) (30.1%) and liposarcoma (34.3%) were the most common histological subtype. The median tumor size were 6 cm (range, 2-30 cm) and 59.6% extremity/trunk STS larger than 5 cm. Twentyone patients (12.7%) were low grade, whereas 145 (87.3%) presented as high grade tumors. Positive margin were found in 14 patients (8.4%). Chemotherapy was given to 9.0% and radiotherapy to 45.8% of patients. The radiation dose ranged from 50 Gy to 66 Gy, with a median dose of 60 Gy. Only one patient developed lymph node metastasis.
There were a relative excess of liposarcoma (57.4% vs. 34.3%; P = 0.004) and leiomyosarcoma (21.3% vs. 3.6%; P < 0.001) in retroperitoneal site and of fibrosarcoma (15.5% vs. 2.1%; P = 0.012) and UPS (30.1% vs. 8.5%; P = 0.003) in extremity/trunk site. Nearly every subtype liposarcoma was more common in retroperitoneal STS. Retroperitoneal STS were significantly larger compared with extremity/trunk STS (median size 18 cm vs. 6 cm; P < 0.001). Patients with the retroperitoneal STS had more positive margin (21.3% vs. 8.4%; P < 0.001) and less often received radiotherapy (2.1% vs. 45.8%; P < 0.001). The distribution of other clinicopathological factors was not significantly different between two cohorts (P > 0.05).
Patients outcomes
The median follow-up time for the entire population was 68 months (range, 5-127 months), with 56 months (range, 7-120 months) in retroperitoneal STS and 67 months (range, 5-127 months) in extremity/trunk STS, respectively. Table 2 presents the patients outcomes. 
Retroperitoneal STS
There were 25 patients experienced local recurrences (53.2%) and all of them were initial site of failure. The median time to local failure was 22 months (range, 3-120 months). The estimated 1-, 2-and 5-year LFFS were 78.1%, 63.1% and 50.0%, respectively. As only one patient received radiotherapy, we excluded radiotherapy in univariate Cox proportional hazards analysis for LFFS. The results showed that higher grade (P = 0.037) and positive margin (P = 0.009) were significant prognostic factors influencing LFFS, with a relative risk of 8.462 and 3.087, respectively (Table 3) . A total of 18 deaths (38.3%) occurred during follow-up, including 17 patients who died of sarcoma-related causes and one died of stroke. Of the 17 patients who died of sarcoma-related causes, 14 patients (82.3%) had local recurrence only and three patients (17.7%) had distant metastases only. The estimated 1-, 2-and 5-year OS were 97.7%, 83.6% and 65.4%, respectively. Positive margin was the only significant risk factor influencing OS with a relative risk of 5.682 (P = 0.001). Compared to liposarcoma, other subtype STS had a tendency of worse OS, with a relative risk of 2.466 (95% CI = 0.867-7.019, P = 0.091) ( Table 4 ). The other clinicopathological factors were not significant in model. Distant metastasis occurred in four patients (8.5%). At 1, 2, and 5 years, the estimated 1-, 2-and 5-year DMFS were 95.7%, 90.5% and 90.5%, respectively. As only few patients developed distant metastasis in retroperitoneal patients, we did not conduct further analysis.
Extremity/trunk STS
In this study, 47 patients (28.3%) experienced local recurrence, including 44 patients had local recurrence as their initial site of failure and two patients detected local recurrence and distant Abbreviations: OS, overall survival; LFFS, local failure-free survival; DMFS, distant metastasis-free survival. metastases concurrently. Of 44 patients with local recurrence as initial site of failure, the median time to local recurrence was 21 months (range, 3-108 months). The estimated 1-, 2-and 5-year LFFS were 89.6%, 83.2% and 74.3%, respectively. Univariate Cox proportional hazard models showed that positive margin (P = 0.036) was associated with poor LFFS and radiotherapy (P = 0.027) was correlated with longer LFFS. A total of 41 patients (24.7%) died during follow-up, including 36 patients who died of sarcoma-related causes. Other causes of death included stroke (one), respiratory failure (one), heart failure (one) and second cancers (two). Of the 36 patients who died of sarcoma-related causes, six patients (16.7%) had local recurrence, 14 distant metastases (38.9%) and 16 both (44.4%). The estimated 1-, 2-and 5-year OS were 97.0%, 92.7% and 77.5%, respectively. Univariate Cox proportional hazards models showed that larger tumor size (P = 0.034) was the only adverse prognostic factor for OS, with a relative risk of 2.164.
Thirty-five patients (21.1%) developed distant metastases, including 19 patients with distant metastasis as their initial site of failure. Of the 19 patients with distant metastases, the median time to distant metastasis was 21 months (range, 3-106 months). The estimated 1-, 2-and 5-year DMFS were 95.8%, 90.2% and 78.9%, respectively. Univariate Cox proportional hazards models for DMFS showed that non-liposarcoma subtype (P = 0.048) and positive margin (P = 0.039) were significant risk factors that influenced DMFS (Supplementary Table 1) .
Comparing all STS, retroperitoneal was an independent significant adverse prognostic factor in LFFS compared to extremity/trunk STS, with 5-year LFFS of 50.0% and 74.3%, respectively (P < 0.001, Fig. 1 ). Retroperitoneal STS was also correlated with worse OS compared to extremity/trunk STS, with 5-year OS of 65.4% and 77.5%, respectively (P = 0.017, Fig. 2) . The two group patients had no difference in developing distant metastasis, with 5-year DMFS of 94.6% and 78.9% in the Retroperitoneal STS and extremity/trunk STS group, respectively (P = 0.386) (Supplementary Fig 1) . There were higher proportional patients experienced local recurrence as initial site of treatment failure in retroperitoneal than extremity/trunk STS group (53.2% vs. 26.5%, P = 0.001). To sarcoma-related mortality, patients with retroperitoneal STS more often died due to local disease progression (82.3%), whereas patients with extremity/trunk STS were less likely to die of local recurrence (16.7%).
Discussions
This study compared the clinicopathological characteristics and treatment outcomes of retroperitoneal and extremity/trunk STS in our patient population. In our results, patients with retroperitoneal STS had larger tumor size, more positive margin, had tumors different histological subtypes and less often received radiotherapy. Retroperitoneal STS was significantly correlated with higher rate of local recurrence and worse overall survival compared to extremity/ trunk STS. Patients with retroperitoneal STS most often died due to local disease progression, whereas patients with extremity/trunk STS were most likely to die of distant metastasis. Although most studies classified STS into retroperitoneal and extremity/trunk location in survival analysis, there were increasing studies compared the survival between the two cohorts. In a study of 10 000 patients with STS, Brennan found tumor location was a major determinant of outcome and pattern of recurrence. Retroperitoneal lesions had a propensity for early and high local recurrence compared to extremity/trunk lesions, with~50% local recurrence recurring within the first five years and~20-25% at 10 years, respectively. In comparison with extremity/trunk STS, the prognosis of retroperitoneal STS was significantly worse (13). Gutierrez reported tumor location was an independent prognostic factor in a study including 8249 cases with STS. Retroperitoneal sarcomas had a more ominous prognosis than did other sites (P < 0.001) (14) . A number of factors may contribute to the worse survival among patients with tumors of retroperitoneal STS.
To explore the reasons for the worse outcomes of retroperitoneal tumors, we compared the clinicopathological factors and failure patterns between retroperitoneal and extremity/trunk STS. We noted that the tumors were significantly larger in retroperitoneal STS compared to extremity/trunk STS group. When retroperitoneal and extremity/trunk STS were aggregated as one entity, the larger tumor size was associated with worse LFFS and OS. However, tumor size lost significant in retroperitoneal STS. Despite this finding, we noted the median tumor size was 18 cm and most patients with tumor larger than 5 cm in retroperitoneal STS. It may be not appropriate to classify retroperitoneal STS size by 5 cm. In fact, the impact of tumor size on survival in patients with STS was controversial. Multiple studies reported retroperitoneal tumors frequently presented with tumors of large size and larger tumor size correlated with worse outcome in patients with STS (13, 15, 16) . However, Lewis et al. reported that there was no association between tumor size and disease specific survival (17) . Keung et al. also noted that tumor size was not a predictor of worse progression free survival, local recurrence-free survival and OS (18) . In our series, larger tumor size may contribute to the worse prognosis of retroperitoneal STS.
We also found positive margin was more common in retroperitoneal STS compared to extremity/trunk STS group (21.3% vs. 8.4%, P = 0.014). Univariate Cox proportional hazard models showed patients with positive margin had significantly worse LFFS and worse OS in retroperitoneal STS. Many studies showed positive surgical margin was predictor of local recurrence. Bonvalot et al. showed that positive margin was a significant variable, predicting higher rate of recurrence and was also associated with decreased OS (19) . Stahl et al. identified 4015 patients to evaluate the effect of microscopic margin status on survival in adult retroperitoneal STS. Multivariable regression showed R0 versus R1 resection was associated with improved survival (20) . Higher rate of positive margin in patients with retroperitoneal STS may be one of the reasons for worse prognosis.
Fewer patients received radiotherapy in retroperitoneal STS group compared to extremity/trunk STS group (2.1% vs. 45.8%; P < 0.001). In univariate Cox proportional hazards models analysis, RT was independent predictor of better LFFS in extremity/trunk STS. These findings echo those of studies performed of patients with extremity/trunk STS, which consistently showed that RT was associated with better LFFS, highlighting the importance of RT in the treatment of STS (4, 5) . Due to only one patient received RT in retroperitoneal STS group, we could not fairly comment on the impact of RT in patients with retroperitoneal STS. In fact, there is currently no Level I evidence for RT in management of retroperitoneal STS. The American College of Surgeons Oncology Group opened a Phase III randomized trial (NCT00091351), comparing surgery alone versus preoperative RT followed by surgery. Unfortunately, the trial closed due to poor accrual. The European Organization for Research and Treatment of Cancer (EORTC) is currently conducting a randomized trial (STRASS trial) comparing 50.4 Gy of preoperative RT followed by surgery to surgery alone, and is currently enrolling patients.
Even though evidence were insufficient, there were many multidisciplinary teams using RT as part of their treatment strategy in retroperitoneal STS, citing the proven efficacy of RT combined with surgery for STS in extremity/trunk (21) (22) (23) (24) (25) . In a case-control, propensity score-matched analysis, Nussbaum et al. reported that both preoperative and postoperative RT were significantly independent predictors for improved OS compared with surgery alone, with HR of 0.70 (95% CI 0.59-0.82, P < 0.0001) and 0.78 (0.71-0.85, P < 0.0001), respectively (25) . Gronchi et al. found RT was a significant independent predictor for local control, but was not a predictor for overall survival in patients with retroperitoneal STS (9) . In a metaanalysis, Albertsmeier et al. reported RT reduced local recurrence in both retroperitoneal tumors and other locations. RT also improved OS in retroperitoneal STS (26) . Fewer patients received RT in retroperitoneal STS group may be another reasons resulted in worse prognosis.
The worse prognosis of retroperitoneal tumors has also been thought to be histopathologically dependent. Biological behavior and outcome varies widely between the different histological subtypes. For all subtypes, the survival data vary highly between the different histological subtypes (27, 28) . In our study, although liposarcoma (P = 0.004) and leiomyosarcoma (P < 0.001) were significantly more common in the retroperitoneal STS, while fibrosarcoma (P = 0.012) and UPS (P = 0.003) were more common in extremity/trunk STS, the histological subtype was not correlated with LFFS in univariate Cox proportional hazards models. Comparing to liposarcoma, other histological subtypes had similar tendency of worse OS in both group, with a relative risk of 2.466 (P = 0.091) and 1.877 (P = 0.084) in retroperitoneal and extremity/ trunk STS group, respectively. Tumor grade were equivalent between two cohorts (P > 0.05). There were also no difference in developing distant metastasis between two cohorts (P = 0.160). All the data indicated that the patients in two groups had similar aggressive disease. The histopathological bias between retroperitoneal STS and extremity/trunk STS was not likely to be the reason for different outcomes.
This study had several limitations. First, this analysis was a retrospective study. Our findings may not be generalizable to other cohorts of patients and thus exposed to bias. Second, only one patient in retroperitoneal STS group received RT, we could not fairly comment on the impact of RT in patients with retroperitoneal STS.
Conclusively, this study compared the clinicopathological characteristics and treatment outcomes in 213 localized primary STS. Our results showed that retroperitoneal STS were correlated with higher rate of local recurrence and worse OS compared with extremity/trunk STS. Larger tumor size, more patients with positive margin and fewer patients received RT in retroperitoneal group may result in worse survival compared to extremity/trunk disease. 
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